OneSource

Bengaluru, India Founded: 2023 • Age: 3 yrs Listed Acquired By 360 One
Pharmaceutical contract development and manufacturing services are offered by OneSource.
Request Access
Report Incorrect Data
Page last updated

About OneSource

OneSource is a publicly listed company based in Bengaluru (India) founded in 2023, and was acquired by 360 One in November 2024. Pharmaceutical contract development and manufacturing services are offered by OneSource. It operates on a Professional Services model. OneSource has raised $155.46 million across 7 funding rounds from investors including 360 One, Tenshi Life Sciences and GMS Holdings. The company has 1,770 employees. Its chief executive, as recorded, is Neeraj Sharma. Its Indian entity Onesource Specialty Pharma Limited reported revenue of ₹1,437 Cr. OneSource offers products and services including Sterile Injectables, Soft Gelatin Capsules, Drug-Device Combinations, and Complex Biologics. Its focus areas include Pharmaceuticals and Contract Development and Manufacturing.

Company details

OneSource is established as a multimodal specialty pharmaceutical CDMO with comprehensive end-to-end capabilities across various technology platforms and therapeutic modalities. Services are provided in drug development, manufacturing, and delivery, covering sterile injectables, soft gelatin capsules, drug-device combinations, and complex biologics. Expertise is offered in process development, quality compliance, and tech transfer, ensuring market-ready solutions. Operations are supported by state-of-the-art facilities and a dedicated team of over 100 scientists and leaders, catering to diverse market demands in the healthcare sector.

  • Headquarters Bengaluru, India
  • Employees 1,770
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    •••• ••••
  • Website onesourcecdmo.com
  • Social LinkedIn
  • Acquired by 360 One (Nov 2024)
  • Legal Name Onesource Specialty Pharma Limited
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹17,999 Cr

    ONESOURCE · NSE

  • Share Price
    ₹1,563.00

    -0.42% today

  • Revenue
    ₹1,422 Cr

    FY 2025-26 · -1.6% YoY

  • EBITDA
    ₹294 Cr

    Margin 20.7%

  • Net Profit
    −₹64.12 Cr

    FY 2025-26 · -161.1% YoY

  • Debt / Equity
    0.17

    Interest cover 803.9x

  • Total Equity Funding
    $155.46M (USD)

    in 7 rounds

  • Latest Funding Round
    $80M (USD), Series C

    Mar 2021

  • Investors
    360 One

    & 13 more

  • Employee Count
    1,770
  • Acquired by
    360 One

    (Nov 2024)

Products & Services of OneSource

OneSource offers a comprehensive portfolio of products and services, including Sterile Injectables, Soft Gelatin Capsules, Drug-Device Combinations, and Complex Biologics.

Sterile Injectables
Pharmaceuticals

Sterile injectables are developed in complex dosage forms.

Soft Gelatin Capsules
Pharmaceuticals

High-quality soft gelatin capsules are produced efficiently yearly.

Drug-Device Combinations
Medical Devices

Drug-device combinations are manufactured with flexible assembly stations.

Complex Biologics
Biologics

Integrated solutions for biologics are offered with expertise.

Funding Insights of OneSource

OneSource has successfully raised a total of $155.46M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $80 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $155.46M
  • Total Rounds 7
  • Last Round Series C — $80M
  • First Round $507,480

    (Dec 2007)

  • Investors Count 13

All 7 funding rounds of OneSource with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2021$80MSeries C–TPG
RouteOne, Think Investments
Nov 2018$42.91MSeries B–Tenshi Life Sciences
GMS Holdings
Feb 2016$31.15MSeries B–GMS Holdings
Tenshi Life Sciences
Jul 2010$167,265Angel Round–Menaka Gubbi
B K Iyer, Tanya Julka
Jun 2009$523,986Seed–Accel
–
Dec 2008$200,090Seed–Erasmic Venture Fund
–
Dec 2007$507,480Seed–Erasmic Venture Fund
–
Valuation history

14 investors in total: 10 institutional and 4 angel.

Investors in OneSource

OneSource has secured backing from 14 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include 360 One, Tenshi Life Sciences and GMS Holdings.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
GMS Holdings
gmsholdings.com
Accel
Accel is recognized as a leading venture capital firm.
accel.com
TPG
Fund of funds focused on pre-seed and seed-stage companies
tpg.com
Think Investments
Investment Firm
thinkinvestments.com
Timf Holdings
Venture capital is focused on auto tech and multiple sectors.
360 One
Asset and wealth management software is provided for businesses.
2008360.oneMumbai, India
Tenshi Life Sciences
Delivers advanced finished dosage pharmaceuticals using global infrastructure and quality systems.
tenshi.co.in
Erasmic Venture Fund
Limited information available
erasmic.com
RouteOne
Web-based credit applications are managed for automotive dealerships.
routeone.com
Medella Holdings
Premium access

Investor details for OneSource

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Onesource Specialty Pharma Limited (OneSource)

Onesource Specialty Pharma Limited is the primary company behind OneSource. The board of Onesource Specialty Pharma Limited currently have 8 directors; the longest-serving is Arun Kumar Pillai, appointed in 2021. 34 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Arun Kumar Pillai
DIN 00084845
Director07 Apr 20215 yrs 6 moOnesource Specialty Pharma Limited
Neeraj Sharma
DIN 09402652
Managing Director01 Mar 20242 yrs 8 moOnesource Specialty Pharma Limited
Rashmi Harshadrai Barbhaiya
DIN 10593871
Director17 May 20242 yrs 5 moOnesource Specialty Pharma Limited
Bharat Dhirajlal Shah
DIN 00136969
Director26 Jul 20242 yrs 3 moOnesource Specialty Pharma Limited
Debarati Sen
DIN 07521172
Director27 Feb 20251 yr 8 moOnesource Specialty Pharma Limited
Claudio Dr Albrecht
DIN 10109819
Director27 Feb 20251 yr 8 moOnesource Specialty Pharma Limited
Vijay Paul Karwal
DIN 10905781
Director27 Feb 20251 yr 8 moOnesource Specialty Pharma Limited
Colin Bond Michael
DIN 10982819
Director23 Jun 20251 yr 4 moOnesource Specialty Pharma Limited

People of OneSource

18 people are tracked at OneSource (11 in leadership, 7 in team); the tracked headcount is 1,770.

NameRoleGroup
Neeraj Sharma
CEO & Managing DirectorLeadership
Rajat Ghosh
Associate Vice President And Head Of Drug Substance ManufacturingLeadership
Jason Spacek
Chief Business OfficerLeadership
Nitin Mittal
Associate Vice PresidentLeadership
Ramesh Chand D.
Corporate Head (director)-audit And ComplianceLeadership
Anurag Bhagania
Chief Financial OfficerLeadership
Ravi Kumar
Head Of StrategyLeadership
Biju Mathew
Chief Quality OfficerLeadership
Prateek Gupta
SVP & Head – Technical DevelopmentLeadership
Murari Madhab Mishra
Chief Human Resources OfficerLeadership
Jeff Wong
Chief Business OfficerLeadership
Yeshwanth Kumar H R
Group LeadTeam
Shanjitha Shanmugasundaram
Senior ExecutiveTeam
Gowrav Gowda
Senior ExecutiveTeam
Amol Biradar
Senior ExecutiveTeam
Manu Kumar A S
Senior ExecutiveTeam
Gautam Prakash
MicrobiologistTeam
Hrithick Raj
Senior Instrumentation EngineerTeam
Premium access

Complete people profiles for OneSource

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of OneSource

OneSource is a publicly listed company on the NSE with ticker symbol ONESOURCE in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date24 Jan 2025
  • Listed onBSE: 544292 · NSE: ONESOURCE
  • Listed entityOneSource Specialty Pharma Limited
  • Exchange sectorHealth technology
  • ISININE013P01021
  • Share price₹1,444.80 (-0.98% on the day) · 2026-10-14
  • Market capitalisation₹16,754 Cr
  • Price to earnings516.5
  • EPS (diluted, trailing year)₹-4.25
  • Volume (last session)104,011

Financials of OneSource

Exchange-reported figures of Onesource Specialty Pharma Limited, the listed company behind OneSource (NSE: ONESOURCE).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,422 Cr
-1.6% YoY
EBITDA
₹294 Cr
-17.1% YoY
Profit After Tax
−₹64.12 Cr
-161.1% YoY
Net Worth
₹5,831 Cr
-0.8% YoY
Total Assets
₹7,346 Cr
+7.5% YoY
Total Debt
₹1,276 Cr
+65.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue1,4221,44517238.7113221.39
Revenue growth-1.6%+740.4%+344.1%-70.7%+517.7%-
EBITDA294355(230)(689)(96.66)(71.35)
EBITDA margin+20.7%+24.6%-133.6%-1780.7%-73.2%-333.6%
Profit before tax(91.97)(67.75)(391)(800)(231)(121)
Net profit(64.12)105(269)(656)(233)(121)
Net profit margin-4.5%+7.3%-156.7%-1695.5%-176.2%-564.9%
EPS (₹)(6.44)(1.57)(97.55)(199.46)(76.14)(783.08)
Balance sheet
Total assets7,3466,8349691,6522,1911,173
Net worth5,8315,8813967851,012776
Total debt1,2767725628641,154386
Cash & bank97.5730160.3379.8317077.77
Net working capital691516(179)(133)25914.20
Cash flow
Cash from operations8.52(67.85)(107)(163)(416)(118)
Cash from investing(495)(201)511(67.72)(692)(207)
Cash from financing359412(391)1181,162381
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue516449428290376327426393
Revenue growth (YoY)+37.4%+37.2%+0.5%-26.0%+12.5%+12.0%--
Other income0.953.802.134.633.045.272.896.72
EBITDA16211991.9210.2310685.6118241.36
EBITDA margin+31.3%+26.5%+21.5%+3.5%+28.3%+26.2%+42.7%+10.5%
Depreciation75.0571.7571.8369.6469.8367.8068.4968.77
Interest34.5630.8122.5138.2333.9627.4833.4145.82
Profit before tax52.8620.28(0.29)(93.01)5.74(4.40)82.81(66.51)
Tax(4.62)(4.70)(4.89)(4.31)(4.74)(4.21)(15.69)2.35
Net profit57.4824.984.60(88.70)10.48(0.19)98.50(68.86)
EPS (₹)5.012.180.40(7.74)0.91(0.02)8.59(6.31)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue1,4051,30017238.7113221.39
Revenue growth+8.1%+655.9%+344.1%-70.7%+517.7%-
EBITDA264246(233)(645)(97.23)(72.04)
EBITDA margin+18.8%+19.0%-135.8%-1667.3%-73.6%-336.8%
Profit before tax21.20(22.14)(390)(799)(230)(121)
Net profit26.50131(269)(642)(230)(121)
Net profit margin+1.9%+10.1%-156.7%-1657.8%-174.0%-566.8%
EPS (₹)1.851.69(97.36)(1,992.80)(58.76)(785.74)
Balance sheet
Total assets7,4746,8819711,6532,1941,176
Net worth5,9505,9203987871,016779
Total debt1,5049425718641,154386
Cash & bank89.9522860.2579.7616977.41
Net working capital649505(177)(132)26012.03
Cash flow
Cash from operations55.18(47.28)(109)(165)(420)(115)
Cash from investing(478)(300)506(65.68)(685)(210)
Cash from financing361417(384)1181,159381
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue514446419290375321477337
Revenue growth (YoY)+37.1%+39.1%-12.2%-13.8%+52.9%+33.7%--
Other income0.923.793.764.623.045.263.915.91
Total expenses356332344284274241241338
EBITDA15811474.705.7410279.87236(1.04)
EBITDA margin+30.8%+25.6%+17.8%+2.0%+27.1%+24.9%+49.5%-0.3%
Depreciation39.0436.1834.7434.5734.2133.2833.5933.98
Interest34.1830.5222.2537.9933.3127.0332.3943.92
Profit before tax86.2051.2221.47(62.20)37.1024.82174(73.03)
Tax0.000.000.000.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 01 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue516449428290376327426393
Revenue growth (YoY)+37.4%+37.2%+0.5%-26.0%+12.5%+12.0%--
Other income0.953.802.134.633.045.272.896.72
EBITDA16211991.9210.2310685.6118241.36
EBITDA margin+31.3%+26.5%+21.5%+3.5%+28.3%+26.2%+42.7%+10.5%
Depreciation75.0571.7571.8369.6469.8367.8068.4968.77
Interest34.5630.8122.5138.2333.9627.4833.4145.82
Profit before tax52.8620.28(0.29)(93.01)5.74(4.40)82.81(66.51)
Tax(4.62)(4.70)(4.89)(4.31)(4.74)(4.21)(15.69)2.35
Net profit57.4824.984.60(88.70)10.48(0.19)98.50(68.86)
EPS (₹)5.012.180.40(7.74)0.91(0.02)8.59(6.31)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue1,4221,44517238.7113221.39
Revenue growth-1.6%+740.4%+344.1%-70.7%+517.7%-
Other income15.0217.474.232.693.771.01
Total expenses1,1271,09040272822992.74
Employee cost0.0021579.3672.8060.9935.60
EBITDA294355(230)(689)(96.66)(71.35)
EBITDA margin+20.7%+24.6%-133.6%-1780.7%-73.2%-333.6%
Depreciation27927476.2965.6870.3534.40
Interest12216689.4547.5568.0315.82
Profit before tax(91.97)(67.75)(391)(800)(231)(121)
Tax(18.16)(49.79)0.000.00(0.11)0.27
Net profit(64.12)105(269)(656)(233)(121)
Net profit margin-4.5%+7.3%-156.7%-1695.5%-176.2%-564.9%
EPS (₹)(6.44)(1.57)(97.55)(199.46)(76.14)(783.08)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital11.4611.444.014.013.041.54
Reserves & surplus5,8195,8693927811,009774
Shareholders' funds (net worth)5,8315,8813967851,012776
Minority interest0.000.000.000.000.000.00
Secured loans1,140658137433597309
Unsecured loans13611442543155776.59
Total debt1,2767725628641,154386
Total liabilities7,3466,8349691,6522,1911,173
Assets
Gross block6,7996,6441,1391,6331,391718
Net block6,0176,1188631,3611,231633
Capital work in progress529218188334490431
Investments15.6815.7919.584.500.000.00
Inventories5332651281392754.89
Sundry debtors69041755.243.8223.642.22
Cash & bank balances97.5730160.3379.8317077.77
Loans & advances19420233.797.1042.2413.83
Total current assets1,5151,18427823051198.71
Total current liabilities82466845736325284.51
Net working capital691516(179)(133)25914.20
Total assets7,3466,8349691,6522,1911,173
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash16522.269.4712267.2911.28
Net cash from operating activities8.52(67.85)(107)(163)(416)(118)
Net cash from investing activities(495)(201)511(67.72)(692)(207)
Net cash from financing activities359412(391)1181,162381
Net change in cash(127)14312.79(112)54.4756.01
Closing cash97.5730160.3379.8317077.77
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-1.6%+740.4%+344.1%-70.7%+517.7%-
EBITDA growth-17.1%+254.6%+66.7%-613.1%-35.5%-
PBT growth-35.8%+82.7%+51.1%-245.9%-91.8%+9997.0%
Net income growth-161.1%+139.0%+59.0%-181.9%-92.7%-
Revenue CAGR (3Y)+232.4%+122.0%+100.3%---
EBITDA CAGR (3Y)--+47.7%---
Profitability & leverage
Net income margin-5.2%-1.2%-227.5%-2066.2%-175.0%-564.9%
Return on capital employed0.0%0.0%0.0%0.0%0.0%0.0%
Return on net worth0.0%0.0%0.0%0.0%0.0%0.0%
Debt / equity0.170.211.211.120.860.72
Long-term debt / equity0.070.080.530.530.510.56
Interest cover803.88205.08-29.24-6.30-40.73-14.96
Efficiency & per share
Fixed asset turnover0.210.370.120.030.130.04
Inventory turnover3.567.351.290.190.948.75
Debtors turnover2.576.125.822.8210.2219.18
EPS (₹)(6.44)(1.57)(97.55)(199.46)(76.14)(783.08)
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)508.70513.9098.68195.87333.495,029.28
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue514446419290375321477337
Revenue growth (YoY)+37.1%+39.1%-12.2%-13.8%+52.9%+33.7%--
Other income0.923.793.764.623.045.263.915.91
Total expenses356332344284274241241338
EBITDA15811474.705.7410279.87236(1.04)
EBITDA margin+30.8%+25.6%+17.8%+2.0%+27.1%+24.9%+49.5%-0.3%
Depreciation39.0436.1834.7434.5734.2133.2833.5933.98
Interest34.1830.5222.2537.9933.3127.0332.3943.92
Profit before tax86.2051.2221.47(62.20)37.1024.82174(73.03)
Tax0.000.000.000.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue1,4051,30017238.7113221.39
Revenue growth+8.1%+655.9%+344.1%-70.7%+517.7%-
Other income15.0127.658.752.705.861.01
Total expenses1,1421,05340568422993.43
Employee cost24021579.3672.8056.9731.22
EBITDA264246(233)(645)(97.23)(72.04)
EBITDA margin+18.8%+19.0%-135.8%-1667.3%-73.6%-336.8%
Depreciation13713576.2910970.3534.40
Interest12116289.4247.5568.0215.80
Profit before tax21.20(22.14)(390)(799)(230)(121)
Tax0.00(41.46)0.000.000.000.00
Net profit26.50131(269)(642)(230)(121)
Net profit margin+1.9%+10.1%-156.7%-1657.8%-174.0%-566.8%
EPS (₹)1.851.69(97.36)(1,992.80)(58.76)(785.74)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital11.4611.444.014.013.911.54
Reserves & surplus5,9385,9093947831,012777
Shareholders' funds (net worth)5,9505,9203987871,016779
Secured loans1,1406581373831,154309
Unsecured loans3642854344810.0076.59
Total debt1,5049425718641,154386
Total liabilities7,4746,8819711,6532,1941,176
Assets
Gross block3,6973,5871,1391,6331,392718
Net block3,1983,2008631,3611,231633
Capital work in progress469206188334440382
Investments2,9312,84819.704.5151.6753.19
Inventories5332601281392634.89
Sundry debtors73544255.413.7436.602.24
Cash & bank balances89.9522860.2579.7616977.41
Loans & advances18719233.747.0543.0713.83
Total current assets1,5461,12227823051298.37
Total current liabilities89761645536125186.34
Net working capital649505(177)(132)26012.03
Total assets7,4746,8819711,6532,1941,176
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash92.0922.199.4112166.9211.17
Net cash from operating activities55.18(47.28)(109)(165)(420)(115)
Net cash from investing activities(478)(300)506(65.68)(685)(210)
Net cash from financing activities361417(384)1181,159381
Net change in cash(61.37)69.9012.78(112)54.5555.76
Closing cash89.9522860.2579.7616977.41
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+8.1%+655.9%+344.1%-70.7%+517.7%-
EBITDA growth+7.0%+205.5%+63.8%-563.8%-35.0%-
PBT growth+9998.0%+94.3%+51.2%-247.8%-89.5%+9997.0%
Net income growth-79.7%+148.5%+58.0%-179.2%-89.6%-
Revenue CAGR (3Y)+231.1%+114.3%+100.3%---
EBITDA CAGR (3Y)--+48.0%---
Profitability & leverage
Net income margin+1.5%+1.5%-227.1%-2064.4%-173.9%-566.8%
Return on capital employed+1.6%+5.2%0.0%0.0%0.0%0.0%
Return on net worth+0.3%+3.2%0.0%0.0%0.0%0.0%
Debt / equity0.210.241.211.120.860.72
Long-term debt / equity0.100.100.540.530.510.56
Interest cover95.12144.51-28.87-6.30-40.59-14.84
Efficiency & per share
Fixed asset turnover0.390.550.120.030.130.04
Inventory turnover3.546.691.290.190.998.75
Debtors turnover2.395.235.811.926.8019.01
EPS (₹)1.851.69(97.36)(1,992.80)(58.76)(785.74)
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)519.07517.3699.191,961.88259.755,045.70

Timeline of OneSource

5 dated milestones of OneSource across 18 years, from founding to its latest funding, stage changes and deals.

  1. Funding First funding round of $507K.
  2. Funding Latest funding round, Series C, of $80.0M.
  3. Founded OneSource is founded.
  4. Exit Acquired by 360 One.
  5. IPO Lists on the stock exchange (IPO).

Web traffic of OneSource

The website of OneSource (onesourcecdmo.com) receives about 4.2K visits a month.

  • Monthly visits
    4.2K

    ▼ 14.3% vs previous month

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as OneSource (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M1,820
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M4,260
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Onesource

ONESOURCE: Gets USFDA EIR With VAI Status, Finishing Inspection At Bengaluru's Sterile Product Division Facility.
Exchange Update • 2 days ago
ONESOURCE: Q2 SL NET PROFIT 862M RUPEES VS 371M (YOY)
Exchange Update • 5 days ago
ONESOURCE: Q2 REVENUE 5.14B RUPEES VS 3.76B (YOY)
Exchange Update • 5 days ago
ONESOURCE: Q2 EBITDA 1.58B RUPEES VS 1B (YOY); Q2 EBITDA MARGIN 30.8% VS 27.07% (YOY)
Exchange Update • 5 days ago
Onesource Specialty: Expects Semaglutide Approvals In Brazil And Turkey Within The Next 2 Quarters.
Exchange Update • 5 days ago
Top Gainers & Losers on 3 August: Urban Company, Pine Labs, Redington, Paytm, TCS, Meesho among top gainers
Mint • 3 months ago
Buy Onesource Specialty Pharma; target of Rs 2400: ICICI Securities
Moneycontrol • 3 months ago
ONESOURCE: Q1FY27 delivered strong growth, with semaglutide and biologics driving revenue and margin gains
Quartr • 3 months ago
ONESOURCE: Q1 revenue and EBITDA surged on strong demand, capacity expansion, and robust outlook
Quartr • 3 months ago
ONESOURCE: Strong revenue growth and profitability rebound, despite ongoing legal dispute
Quartr • 3 months ago
Premium access

Complete news archive for OneSource

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about OneSource

OneSource was founded in 2023.

OneSource is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.

Neeraj Sharma is the CEO of OneSource, as recorded in our data.

OneSource is a funded company, having raised a total of $155.46M across 7 funding rounds to date. The company's 1st funding round was a Seed of $507.48K, raised on Dec 2007.

OneSource has 1,770 employees.

The primary company behind OneSource, Onesource Specialty Pharma Limited, reported revenue of ₹1,437 Cr for FY 2026, down 2% year on year.

OneSource is established as a multimodal specialty pharmaceutical CDMO with comprehensive end-to-end capabilities across various technology platforms and therapeutic modalities. Services are provided in drug development, manufacturing, and delivery, covering sterile injectables, soft gelatin capsules, drug-device combinations, and complex biologics. Expertise is offered in process development, quality compliance, and tech transfer, ensuring market-ready solutions. Operations are supported by state-of-the-art facilities and a dedicated team of over 100 scientists and leaders, catering to diverse market demands in the healthcare sector.

OneSource offers Sterile Injectables, Soft Gelatin Capsules, Drug-Device Combinations, and Complex Biologics.

Yes, OneSource is publicly traded on NSE under the ticker symbol ONESOURCE.

OneSource has 14 investors. Key investors include 360 One, Tenshi Life Sciences, GMS Holdings, Menaka Gubbi, and B K Iyer.

OneSource operates through Onesource Specialty Pharma Limited.

Yes. OneSource was acquired by 360 One in November 2024.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available